Clinical Outcomes of PRX S With Standardized Home Care in Mild-to-Moderate Facial Acne. (PRXS-SINGLE)
Changes in Inflammatory Lesion Count, Tolerability, and Clinical and Instrumental Skin Parameters Following Five PRX S Sessions Combined With Standardized Home Care in Adults With Mild-to-Moderate Facial Acne: A Prospective, Single-Arm, Open-Label Clinical Study.
This study aims to assess changes in facial acne lesions and skin condition following a series of five PRX S treatments combined with standardized home skin care in adults with mild-to-moderate acne.
The study will include 30 adults aged 18-60 years with mild-to-moderate facial acne. All participants will receive five PRX S treatments at two-week intervals and use the same home-care products, including a nourishing cream and an active Balancing Cream.
The main objective is to determine how the number of inflammatory acne lesions (papules and pustules) changes from the beginning of the study to two weeks after the fifth treatment. The study will also assess other acne lesions, overall acne severity, skin oiliness, hydration, elasticity, skin surface characteristics, and skin thickness using clinical examinations and specialized instruments. Skin tolerability and any adverse events will also be monitored.
Participants will undergo assessments before treatment, after three completed treatments, two weeks after the fifth treatment, and approximately two months later.
All participants will receive the same treatment regimen. There will be no placebo or untreated comparison group. Therefore, the study will describe changes observed during the combined treatment program but will not determine the separate effects of PRX S or establish its superiority over other treatments.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
This study aims to assess changes in facial acne lesions and skin condition following a series of five PRX S treatments combined with standardized home skin care in adults with mild-to-moderate acne.
The study will include 30 adults aged 18-60 years with mild-to-moderate facial acne. All participants will receive five PRX S treatments at two-week intervals and use the same home-care products, including a nourishing cream and an active Balancing Cream.
The main objective is to determine how the number of inflammatory acne lesions (papules and pustules) changes from the beginning of the study to two weeks after the fifth treatment. The study will also assess other acne lesions, overall acne severity, skin oiliness, hydration, elasticity, skin surface characteristics, and skin thickness using clinical examinations and specialized instruments. Skin tolerability and any adverse events will also be monitored.
Participants will undergo assessments before treatment, after three completed treatments, two weeks after the fifth treatment, and approximately two months later.
All participants will receive the same treatment regimen. There will be no placebo or untreated comparison group. Therefore, the study will describe changes observed during the combined treatment program but will not determine the separate effects of PRX S or establish its superiority over other treatments.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Anna Deda, PhD
- Numer telefonu: +48 500 233 457
- E-mail: adeda@sum.edu.pl
Lokalizacje studiów
-
-
-
Mysłowice, Polska, 41-400
- AJ Med
-
Kontakt:
- Anna Deda
- Numer telefonu: +48 500 233 457
- E-mail: adeda@sum.edu.pl
-
Sosnowiec, Polska, 41-208
- Department of Practical Cosmetology and Skin Diagnostics
-
Kontakt:
- Anna Deda, PhD
- Numer telefonu: +48 500 233 457
- E-mail: adeda@sum.edu.pl
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Adults aged 18-60 years.
- Mild-to-moderate facial acne vulgaris, defined as Investigator's Global Assessment (IGA) grade 2 or 3, confirmed by a dermatologist at baseline (T0).
- Presence of at least five inflammatory facial acne lesions (papules and/or pustules) at baseline.
- Provision of written informed consent to participate in the study and undergo study-related assessments and documentation.
- No contraindications to the study products and confirmation by a dermatologist that the treatment regimen is clinically appropriate.
- Ability and willingness to attend scheduled study visits and comply with the standardized home skin-care regimen.
- No urgent need for alternative acne treatment that is not provided within the study protocol.
Exclusion Criteria:
- Investigator's Global Assessment (IGA) grade 0, 1, or 4.
- Severe or nodulocystic acne, deep inflammatory lesions, or rapidly progressive acne scarring requiring alternative medical management.
- Pregnancy or breastfeeding.
- Known hypersensitivity to any component of the study products.
- Active herpes simplex infection, other skin infections, wounds, erosions, or burns in the treatment area.
- Active atopic dermatitis, seborrheic dermatitis, or other skin conditions that may interfere with study assessments.
- Skin malignancy or suspicious lesions in the treatment area.
- Medical conditions or concurrent therapies that may significantly increase treatment-related risks or interfere with the interpretation of study outcomes.
- Use of topical retinoids within 30 days before baseline (T0).
- Completion of anti-acne antibiotic therapy less than 3 months before baseline (T0).
- Completion of isotretinoin therapy less than 6 months before baseline (T0).
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: PRX S Treatment Combined With Standardized Home Care
Participants will receive five professional PRX S facial treatments at approximately 14-day intervals (days 0, 14, 28, 42, and 56), combined with standardized home skin care consisting of WIQO Nourishing Cream for Normal and Combination Skin applied in the morning and WIQO Balancing Cream applied in the evening. Home care will continue throughout the study, including the follow-up period. Clinical and instrumental assessments will be performed at baseline (T0), after three completed treatments (T1), two weeks after the fifth treatment (T2), and two calendar months after T2 (T3). All participants will receive the same combined regimen, with no placebo or comparator group. |
PRX S is a two-phase topical preparation activated immediately before professional application according to the manufacturer's instructions for use. Participants will undergo five facial treatment sessions at approximately 14-day intervals (days 0, 14, 28, 42, and 56). The procedure will be performed using a standardized protocol appropriate for mild-to-moderate facial acne. The application technique, treatment quantity, and number of layers will follow the approved standard operating procedure and current manufacturer's instructions. All participants will follow a standardized home skin-care regimen using WIQO Nourishing Cream for Normal and Combination Skin and WIQO Balancing Cream. The nourishing cream will be used in the morning and the Balancing Cream in the evening according to the approved study instructions. Home care will continue throughout the treatment and follow-up periods. The regimen will be identical for all participants. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change From Baseline in Inflammatory Facial Acne Lesion Count at Day 70
Ramy czasowe: Baseline (Day 0) and Day 70 (14 days after the fifth treatment)
|
The outcome is the within-participant change in the total number of inflammatory facial acne lesions (papules and pustules) between baseline (T0) and T2. Lesions will be counted by a trained dermatologist using a standardized facial lesion-counting procedure. The change will be calculated as the T2 lesion count minus the baseline lesion count. A negative value indicates a reduction in inflammatory lesions. |
Baseline (Day 0) and Day 70 (14 days after the fifth treatment)
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change From Baseline in Inflammatory Facial Acne Lesion Count at Day 42
Ramy czasowe: Baseline (Day 0) and Day 42 (after three completed treatments, before the fourth treatment).
|
Change in the total number of facial inflammatory acne lesions (papules and pustules), counted by a trained dermatologist. The change is calculated as the Day 42 count minus the baseline count. Negative values indicate improvement. |
Baseline (Day 0) and Day 42 (after three completed treatments, before the fourth treatment).
|
|
Change From Baseline in Inflammatory Facial Acne Lesion Count at Follow-up
Ramy czasowe: Baseline (Day 0) and T3 (two calendar months after Day 70).
|
Change in the total number of facial inflammatory acne lesions (papules and pustules) between baseline and T3, assessed by a trained dermatologist using standardized lesion counting. Negative values indicate a reduction in inflammatory lesions. |
Baseline (Day 0) and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Facial Comedone Count
Ramy czasowe: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Change in the total number of non-inflammatory facial acne lesions, including open and closed comedones, assessed by a trained dermatologist using standardized lesion counting. The change at each post-baseline visit is calculated as the visit count minus the baseline count. Negative values indicate fewer comedones. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Percentage Reduction From Baseline in Inflammatory Facial Acne Lesion Count
Ramy czasowe: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Percentage reduction in the total number of facial inflammatory acne lesions (papules and pustules), calculated as 100 × (baseline lesion count - post-baseline lesion count) / baseline lesion count. Positive values indicate a reduction in inflammatory lesions. Participants are required to have at least five inflammatory lesions at baseline. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change in Investigator's Global Assessment of Acne Severity
Ramy czasowe: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Acne severity will be assessed by a dermatologist using the static Investigator's Global Assessment (IGA) scale ranging from 0 (clear) to 4 (severe). The distribution of IGA grades and changes in grades from baseline will be reported at each assessment visit. Lower grades indicate less severe acne. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Percentage of Participants Achieving an Investigator's Global Assessment Grade of 0 or 1
Ramy czasowe: Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Percentage of evaluable participants achieving an Investigator's Global Assessment (IGA) grade of 0 (clear) or 1 (almost clear) at each post-baseline assessment. IGA is a five-category ordinal scale ranging from 0 (clear) to 4 (severe). |
Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Percentage of Participants Achieving Investigator's Global Assessment Success
Ramy czasowe: Day 42, Day 70, and T3 (two calendar months after Day 70).
|
IGA success is defined as achieving an Investigator's Global Assessment grade of 0 (clear) or 1 (almost clear), together with an improvement of at least two grades from baseline. Participants with baseline IGA 2 must achieve grade 0, while participants with baseline IGA 3 may achieve grade 0 or 1. |
Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Facial Skin Sebum Level Measured by Sebumetry
Ramy czasowe: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Facial skin surface sebum will be measured using a sebumeter under standardized measurement conditions. Results will be expressed in micrograms per square centimeter (µg/cm²). Changes from baseline will be calculated at each post-baseline assessment. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Stratum Corneum Hydration Measured by Corneometry
Ramy czasowe: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Skin hydration will be assessed using corneometry under standardized measurement conditions. Measurements reflect hydration of the stratum corneum and are expressed in instrument-specific arbitrary units. Changes from baseline will be calculated at each post-baseline assessment. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Skin Elasticity (Cutometer R2 Parameter)
Ramy czasowe: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Skin biomechanical properties will be assessed using a Cutometer. The R2 parameter, representing gross skin elasticity, will be recorded as a dimensionless ratio. Changes from baseline will be calculated at each post-baseline assessment. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Dermal Thickness Measured by Skin Ultrasonography
Ramy czasowe: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Dermal thickness will be measured using skin ultrasonography at standardized anatomical measurement sites. Results will be expressed in millimeters (mm). Changes from baseline will be calculated at each post-baseline assessment. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Dermal Echogenicity Measured by Skin Ultrasonography
Ramy czasowe: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Dermal echogenicity will be assessed using skin ultrasonography under standardized acquisition conditions. Results will be expressed in instrument-specific arbitrary units. Changes from baseline will be calculated at each post-baseline assessment. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Facial Skin Surface Parameters Assessed by Antera 3D
Ramy czasowe: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Changes in facial skin surface characteristics, including pore-related parameters, skin texture, and surface roughness, will be assessed using the Antera 3D imaging system. Measurements will be performed at standardized anatomical sites and compared with baseline values. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Śledczy
Śledczy
- Główny śledczy: Anna Deda, PhD, Medical University of Silesia in Katowice, Poland
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- PRXS-SINGLE-2026-01
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
De-identified individual participant data underlying the reported study results may be made available to qualified researchers upon reasonable request, subject to participant consent, applicable data protection requirements, and authorization by the study sponsor. Data sharing will be considered on a case-by-case basis.
Ramy czasowe udostępniania IPD
De-identified individual participant data may be made available upon reasonable request following publication of the main study results, subject to participant consent, applicable data protection requirements, and sponsor authorization. The duration of availability will be determined in accordance with the sponsor's data retention and sharing policies.
Kryteria dostępu do udostępniania IPD
De-identified individual participant data underlying the published study results may be made available to qualified researchers upon reasonable request. Requests will be reviewed on a case-by-case basis and will be subject to participant consent, applicable data protection requirements, and authorization by the study sponsor. Access will be limited to data approved for sharing. Participant-identifiable information and identifiable facial photographs will not be shared without the appropriate consent and legal basis.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .